Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment

PURPOSE: High tumor burden has emerged as a negative predictor of efficacy in chimeric antigen receptor T-cell therapy (CART) in patients with refractory or relapsed large B-cell lymphoma. This study analyzed the deviation among imaging-based tumor burden (TB) metrics and their association with prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkelmann, Michael, Bücklein, Veit L., Blumenberg, Viktoria, Rejeski, Kai, Ruzicka, Michael, Unterrainer, Marcus, Schmidt, Christian, Dekorsy, Franziska J., Bartenstein, Peter, Ricke, Jens, von Bergwelt-Baildon, Michael, Subklewe, Marion, Kunz, Wolfgang G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492918/
https://www.ncbi.nlm.nih.gov/pubmed/36158658
http://dx.doi.org/10.3389/fonc.2022.974029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492918/
https://www.ncbi.nlm.nih.gov/pubmed/36158658
http://dx.doi.org/10.3389/fonc.2022.974029

Ejemplares similares